Evaluating IPMN and pancreatic carcinoma utilizing quantitative histopathology
AuthorGlazer, Evan S.
Zhang, Hao Helen
Hill, Kimberly A.
Kha, Stephanie T.
Yozwiak, Michael L.
Nafissi, Nellie N.
Watkins, Joseph C.
Alberts, David S.
Krouse, Robert S.
KeywordsIntraductal papillary mucinous neoplasms
MetadataShow full item record
CitationEvaluating IPMN and pancreatic carcinoma utilizing quantitative histopathology 2016, 5 (10):2841 Cancer Medicine
RightsThis is an open access article under the terms of the Creative Commons Attribution License.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractIntraductal papillary mucinous neoplasms (IPMN) are pancreatic lesions with uncertain biologic behavior. This study sought objective, accurate prediction tools, through the use of quantitative histopathological signatures of nuclear images, for classifying lesions as chronic pancreatitis (CP), IPMN, or pancreatic carcinoma (PC). Forty-four pancreatic resection patients were retrospectively identified for this study (12 CP; 16 IPMN; 16 PC). Regularized multinomial regression quantitatively classified each specimen as CP, IPMN, or PC in an automated, blinded fashion. Classification certainty was determined by subtracting the smallest classification probability from the largest probability (of the three groups). The certainty function varied from 1.0 (perfectly classified) to 0.0 (random). From each lesion, 180 +/- 22 nuclei were imaged. Overall classification accuracy was 89.6% with six unique nuclear features. No CP cases were misclassified, 1/16 IPMN cases were misclassified, and 4/16 PC cases were misclassified. Certainty function was 0.75 +/- 0.16 for correctly classified lesions and 0.47 +/- 0.10 for incorrectly classified lesions (P = 0.0005). Uncertainty was identified in four of the five misclassified lesions. Quantitative histopathology provides a robust, novel method to distinguish among CP, IPMN, and PC with a quantitative measure of uncertainty. This may be useful when there is uncertainty in diagnosis.
NoteOpen Access Journal.
VersionFinal published version
SponsorsNational Cancer Institute (Arizona Cancer Center) [CA023074]; National Institutes of Health, Bethesda, MD [T35HL007479]; National Science Foundation, Arlington, VA [NSF DMS-1309507, NSF DMS-1418172]; Graduate Medical Education Office at the University of Arizona; Jim Click Family Foundation, Tucson, AZ; J. Russell Skelton Family, Phoenix, AZ
- Management of intraductal papillary-mucinous neoplasm of the pancreas: treatment strategy based on morphologic classification.
- Authors: Serikawa M, Sasaki T, Fujimoto Y, Kuwahara K, Chayama K
- Issue date: 2006 Oct
- The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
- Authors: Yamaguchi H, Kuboki Y, Hatori T, Yamamoto M, Shimizu K, Shiratori K, Shibata N, Shimizu M, Furukawa T
- Issue date: 2013 Nov
- Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade.
- Authors: Michaels PJ, Brachtel EF, Bounds BC, Brugge WR, Pitman MB
- Issue date: 2006 Jun 25
- Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: implications of minimal involvement of the main pancreatic duct.
- Authors: Sahora K, Fernández-del Castillo C, Dong F, Marchegiani G, Thayer SP, Ferrone CR, Sahani DV, Brugge WR, Warshaw AL, Lillemoe KD, Mino-Kenudson M
- Issue date: 2014 Sep
- Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types.
- Authors: Ban S, Naitoh Y, Mino-Kenudson M, Sakurai T, Kuroda M, Koyama I, Lauwers GY, Shimizu M
- Issue date: 2006 Dec